<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Valganciclovir: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Valganciclovir: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Valganciclovir: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11135" href="/d/html/11135.html" rel="external">see "Valganciclovir: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13002" href="/d/html/13002.html" rel="external">see "Valganciclovir: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708869"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with valganciclovir.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Impairment of fertility:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Based on animal data and limited human data, valganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Based on animal data, valganciclovir has the potential to cause birth defects in humans.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mutagenesis and carcinogenesis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Based on animal data, valganciclovir has the potential to cause cancers in humans.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F232941"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Valcyte</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868554"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-ValGANciclovir [DSC];</li>
<li>AURO-Valganciclovir;</li>
<li>Auro-Valganciclovir;</li>
<li>MINT-Valganciclovir;</li>
<li>TEVA-ValGANciclovir;</li>
<li>Valcyte</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F232963"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiviral Agent</li></ul></div>
<div class="block doa drugH1Div" id="F232945"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="57386eb2-a83c-45fc-adfa-5d30fd5bb8e0">Cytomegalovirus, mild to moderate, treatment in solid organ transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, mild to moderate, treatment in solid organ transplant recipients (off-label use):</b>
<b>Oral:</b> 900 mg twice daily until symptom resolution and 1 or 2 consecutive weekly undetectable CMV viral load samples are obtained and clinical resolution of disease (minimum treatment course: 2 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-29596116'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69725f51-5e30-4d1c-8231-1a734cb7121c">Cytomegalovirus, preemptive therapy in hematopoietic cell transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, preemptive therapy in hematopoietic cell transplant recipients (off-label use): Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>&lt;100 days post-transplant:</i> 900 mg twice daily for 7 days (autologous transplant) or 7 to 14 days (allogenic transplant), then 900 mg once daily for 1 to 2 weeks or until the indicator test is negative (minimum total induction and maintenance treatment is 2 weeks when 14 days of twice daily is used and 3 weeks when a 7-day induction course is used) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>&gt;100 days post-transplant:</i> 900 mg twice daily for 7 to 14 days, then 900 mg once daily for 1 to 2 weeks or until the indicator test is negative (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="579a31de-a122-4dca-8d19-3ee1d1147d09">Cytomegalovirus, prophylaxis in solid organ transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, prophylaxis in solid organ transplant recipients:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">900 mg once daily; duration of prophylaxis is dependent on type of transplant, as well as donor and recipient CMV serostatus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-29596116'])">Ref</a></span>). <b>Note:</b> Based on limited data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27639246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27639246'])">Ref</a></span>), some centers utilize a lower dose of 450 mg once daily in intermediate-risk (CMV-seropositive [CMV R+] transplant recipients). This dosing strategy has not been studied prospectively and has only been primarily described in renal transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23640298','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23640298','lexi-content-ref-29596116'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c16cca7-c36a-4736-bba1-44d3f3cc65e3">Cytomegalovirus, treatment, esophagitis or colitis in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, treatment, esophagitis or colitis in patients with HIV (off-label use):</b>
<b>Oral:</b> Treat initially with ganciclovir IV; once patient is able to absorb and tolerate oral therapy, may switch to oral valganciclovir 900 mg twice daily for a total duration of 21 to 42 days, or until signs and symptoms have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0dc7876b-bafe-46e9-b2a8-fca20d20c0df">Cytomegalovirus retinitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus retinitis, treatment:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Induction: 900 mg twice daily for 14 to 21 days followed by maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: 900 mg once daily; may consider discontinuation of chronic maintenance therapy in patients that have received 3 to 6 months of treatment, have inactive lesions, and CD4 count &gt;100 cells/mm<sup>3</sup> for 3 to 6 months in response to antiretroviral therapy. Discontinue only after consultation with an ophthalmologist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991220"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing recommendations are based on CrCl as calculated by the Cockcroft-Gault equation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Dose adjustments based on Modification of Diet in Renal Disease Study equation eGFR have been associated with underdosing and subtherapeutic drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23733466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23733466'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:center;">
<b>Valganciclovir Dose Adjustments for Altered Kidney Function (manufacturer's labeling)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">Induction/treatment dose<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Maintenance/prophylaxis dose<sup>a</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> The optimal dose adjustments for valganciclovir are not well defined. Data suggest an increased risk for cytomegalovirus infection among patients with renal dysfunction, possibly associated with valganciclovir renal dose adjustment (Posadas Salas 2013; Schaenman 2020). A pharmacokinetic study with Monte Carlo simulations of different dose adjustments in kidney impairment suggests using valganciclovir doses higher than manufacturer-recommended dosing in order to achieve target exposure. However, the risks and benefits of utilizing higher doses have not been evaluated and are likely to be patient specific (Tängdén 2018).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">≥60 (mL/minute)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">900 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">900 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">40 to &lt;60 (mL/minute)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">450 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">450 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">25 to &lt;40 (mL/minute)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">450 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">450 mg every 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">10 to &lt;25 (mL/minute)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">450 mg every 2 days</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">450 mg twice <b>weekly</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">&lt;10 (mL/minute)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Not recommended by manufacturer; may consider using oral solution 200 mg 3 times weekly (Lucas 2014)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Not recommended by manufacturer; may consider using oral solution 100 mg 3 times weekly (Lucas 2014)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (50%; (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12189361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12189361'])">Ref</a></span>)). Avoid use per manufacturer labeling. Alternatively, consider using valganciclovir oral solution 200 mg (induction/treatment) or 100 mg (maintenance/prophylaxis) 3 times per week (after dialysis on dialysis days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Extent of dialyzability is unknown: Use generally should be avoided; however, if necessary, in the absence of peritoneal dialysis patient-specific data, may consider utilizing doses recommended for CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Avoid use due to substantial interpatient variability in pharmacokinetic parameters (Jarrell 2020); recommend treatment with ganciclovir instead (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use due to anticipated substantial interpatient variability in pharmacokinetic parameters; recommend treatment with ganciclovir instead (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988432"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F232946"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F9515067"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13002" href="/d/html/13002.html" rel="external">see "Valganciclovir: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Valganciclovir oral solution is the preferred oral dosage form in pediatric patients for accuracy in dosing; round to the nearest 25 mg for use with manufacturer-provided oral dispenser. Valganciclovir tablets can be considered if the calculated dose is within 10% of the available tablet strength (450 mg per tablet).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="399c3220-c13b-4327-b7c8-025f5ef0252e">Congenital cytomegalovirus infection, treatment, continuation from neonatal period</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital cytomegalovirus (CMV) infection, treatment, continuation from neonatal period:</b> Limited data available: Infants 1 to 6 months: Oral: 16 mg/kg/dose every 12 hours for 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17392728','lexi-content-ref-Bradley.2019','lexi-content-ref-HHS.1','lexi-content-ref-18279073','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17392728','lexi-content-ref-Bradley.2019','lexi-content-ref-HHS.1','lexi-content-ref-18279073','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on a pharmacokinetic study of 24 neonates which demonstrated that 16 mg/kg/dose twice daily produced similar serum concentrations to ganciclovir 6 mg/kg IV twice daily with a 6-week recommended duration of therapy based on ganciclovir experience (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17392728','lexi-content-ref-HHS.1','lexi-content-ref-18279073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17392728','lexi-content-ref-HHS.1','lexi-content-ref-18279073'])">Ref</a></span>). A longer duration of therapy (6 months) was evaluated in a randomized trial of 96 neonates (GA &gt;32 weeks weighing ≥1.8 kg; PNA at time of therapy initiation &lt;30 days) which compared treatment with 6 weeks of therapy (n=47) to 6 months of therapy (n=49); results demonstrated a modest improvement in long-term hearing and developmental outcomes (evaluated at 12 and 24 months of age) with the longer duration of therapy (6-month course); however, short-term improvement (evaluated at 6 months of age) in hearing was not demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25738669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25738669'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d084c08-c39b-4194-b594-1a1c2f5e615e">Cytomegalovirus disease, mild to moderate, treatment in solid organ transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (CMV) disease, mild to moderate, treatment in solid organ transplant recipients </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-29596116'])">Ref</a></span>): Limited data available: <b>Note: </b>Limit CrCl value used in equation below to 150 mL/minute/1.73 m<sup>2</sup> regardless of CrCl calculated in order to avoid overexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30076649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30076649'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: Dosing based on BSA and CrCl calculation using modified Schwartz formula which bases k constant on age*:</p>
<p style="text-indent:-2em;margin-left:6em;">Dose (mg) = 7 × BSA × CrCl* administered every 12 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum dose: 900 mg/<b>dose</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Continue therapy for ≥2 weeks, until symptoms resolve, and until 1 to 2 weekly CMV viral load samples are undetectable or below a test-specific threshold; may also be used as step-down therapy in patients who initially received IV ganciclovir when clinical and virologic control is adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-29596116'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c16cca7-c36a-4736-bba1-44d3f3cc65e3">Cytomegalovirus, treatment, esophagitis or colitis in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (CMV), treatment, esophagitis or colitis in patients with HIV:</b> Adolescents: Oral: Treat initially with ganciclovir IV; once patient is able to absorb and tolerate oral therapy, may switch to oral valganciclovir 900 mg twice daily for a total duration of 21 to 42 days, or until signs and symptoms have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69725f51-5e30-4d1c-8231-1a734cb7121c">Cytomegalovirus, preemptive therapy in hematopoietic cell transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (CMV), preemptive therapy in </b>
<b>hematopoietic cell transplant recipients:</b> Limited data available: <b>Note:</b> Valganciclovir should be avoided in patients with CMV gastritis or intestinal graft-versus-host disease (GVHD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26207778','lexi-content-ref-28060118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26207778','lexi-content-ref-28060118'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BSA-based dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26207778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26207778'])">Ref</a></span>): Infants ≥9 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance (following induction): Oral: Dosing based on BSA and CrCl calculation using modified Schwartz formula which bases k constant on age*:</p>
<p style="text-indent:-2em;margin-left:8em;">Dose (mg) = 7 × BSA × CrCl* administered every 12 hours; use a maximum of 150 mL/minute/1.73 m<sup>2</sup> for CrCl in equation even if calculated value is higher.</p>
<p style="text-indent:-2em;margin-left:8em;">Maximum dose: 900 mg/<b>dose</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Dosing based on a retrospective evaluation of 46 patients who received preemptive therapy upon CMV reactivation; patients were screened for CMV DNA twice weekly starting 9 days prior to transplantation; 40 of the 46 patients received initial IV induction therapy with ganciclovir; 22 patients received only ganciclovir and 24 patients received valganciclovir; outcomes were similar between the groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26207778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26207778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>): Children and Adolescents weighing ≥40 kg: <b>Note: </b>Only use in patients with good oral intake.</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;100 days post-transplant:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Induction</i>: Oral: 900 mg twice daily for 7 days (autologous transplant) or 7 to 14 days (allogenic transplant).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance:</i> Oral: 900 mg once daily for 1 to 2 weeks or until the indicator test is negative (minimum total induction and maintenance treatment for autologous transplant is 2 weeks; for allogeneic transplants minimum is 2 weeks when 14 days of twice-daily therapy is used and 3 weeks when a 7-day induction course is used).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;100 days post-transplant:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Induction:</i> Oral: 900 mg twice daily for 7 to 14 days.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance:</i> Oral: 900 mg once daily for 1 to 2 weeks until the indicator test is negative (minimum treatment course is 2 weeks).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e71107b-5a0a-450e-8318-3d66932eedcf">Cytomegalovirus, primary prophylaxis in HIV-exposed/-infected patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (CMV), primary prophylaxis in HIV-exposed/-infected patients:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months, Children, and Adolescents ≤16 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>): Oral: Dosing based on BSA and CrCl calculation using modified Schwartz formula which bases k constant on age*:</p>
<p style="text-indent:-2em;margin-left:6em;">Dose (mg) = 7 × BSA × CrCl* administered once daily; use a maximum of 150 mL/minute/1.73 m<sup>2</sup> for CrCl in the equation even if calculated value is higher.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum daily dose: 900 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Primary prophylaxis can be considered in in CMV-seropositive patients &lt;6 years of age who have a CD4 percentage &lt;5% <b>or </b>≥6 years of age who have CD4 cell counts &lt;50 cells/mm<sup>3</sup>. Discontinuation of primary prophylaxis can be considered when CD4 cell count is &gt;10% in &lt;6 years of age <b>or</b> &gt;100 cells/mm<sup>3</sup> for children ≥6 years of age. Secondary prophylaxis may be considered in patients with prior disseminated disease, retinitis, neurologic disease, or GI disease with relapse.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="579a31de-a122-4dca-8d19-3ee1d1147d09">Cytomegalovirus, prophylaxis in solid organ transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (CMV), prophylaxis in solid organ transplant recipients:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> To avoid supratherapeutic exposure, especially in patients with normal renal function and low body weight, the CrCl used in dosage calculations should be capped; most hospitals with pediatric solid organ transplant recipients limit the CrCl used to calculate dosage to a value of 150 mL/minute/1.73 m<sup>2</sup>, regardless of value calculated with the Schwartz equation, to avoid overexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30076649','lexi-content-ref-19260840','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30076649','lexi-content-ref-19260840','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available except for kidney and heart transplants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-20477976','lexi-content-ref-29596116','lexi-content-ref-19260840','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-20477976','lexi-content-ref-29596116','lexi-content-ref-19260840','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Dosing based on BSA and CrCl calculation using modified Schwartz formula which bases k constant on age*:</p>
<p style="text-indent:-2em;margin-left:8em;">Dose (mg) = 7 × BSA × CrCl* administered once daily</p>
<p style="text-indent:-2em;margin-left:8em;">Maximum daily dose: 900 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Initiate therapy within 10 days after transplant; duration of prophylaxis varies depending on organ(s) transplanted, donor and recipient CMV serostatus, and immunosuppressive regimen; typically continued for 3 to 6 months; may be continued up to 12 months in certain cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817026','lexi-content-ref-29596116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817026','lexi-content-ref-29596116'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0dc7876b-bafe-46e9-b2a8-fca20d20c0df">Cytomegalovirus retinitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus (CMV) retinitis, treatment (AIDS-related):</b> Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Induction (active retinitis): Oral: 900 mg twice daily for 14 to 21 days followed by maintenance therapy. For patients with immediate sight-threatening lesions, concomitant use of intravitreal ganciclovir is required.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: Oral: 900 mg once daily; may consider discontinuation of chronic maintenance therapy in patients who have received 3 to 6 months of treatment, have inactive lesions, and CD4 count &gt;100 cells/mm<sup>3</sup> for 3 to 6 months in response to antiretroviral therapy. Discontinue only after consultation with an ophthalmologist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<span style="text-decoration: underline">*CrCl calculation (based on the modified Schwartz formula):</span></b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl (mL/minute/1.73 m<sup>2</sup>) = [k × height (cm)] ÷ SCr (mg/dL)</p>
<p style="text-indent:-2em;margin-left:4em;">Calculated using a modified Schwartz formula where k =</p>
<p style="text-indent:-2em;margin-left:6em;">• 0.33 in infants &lt;1 year of age with low birthweight for GA</p>
<p style="text-indent:-2em;margin-left:6em;">• 0.45 in infants &lt;1 year of age with birthweight appropriate for GA</p>
<p style="text-indent:-2em;margin-left:6em;">• 0.45 in children 1 to &lt;2 years</p>
<p style="text-indent:-2em;margin-left:6em;">• 0.55 in boys age 2 to &lt;13 years</p>
<p style="text-indent:-2em;margin-left:6em;">• 0.55 in girls age 2 to &lt;16 years</p>
<p style="text-indent:-2em;margin-left:6em;">• 0.7 in boys age 13 to 16 years</p></div>
<div class="block dorp drugH1Div" id="F51193226"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥1 month, Children, and Adolescents ≤16 years: BSA and CrCl based dosing calculation: No additional dosage adjustments required; dosing equation adjusts for renal function using modified Schwartz equation*.</p>
<p style="text-indent:-2em;margin-left:2em;">Adolescents &gt;16 years (tablet formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Induction dose:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to 59 mL/minute: 450 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 25 to 39 mL/minute: 450 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 24 mL/minute: 450 mg every 2 days.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute:</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling: Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate recommendations: HIV-1 infected persons: Consider valganciclovir solution 200 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD):</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling: Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate recommendations: HIV-1 infected persons: Consider valganciclovir solution 200 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519'])">Ref</a></span>); valganciclovir is dialyzable and should be administered following dialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance/prevention dose:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to 59 mL/minute: 450 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 25 to 39 mL/minute: 450 mg every 2 days.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 24 mL/minute: 450 mg twice weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute:</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling: Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate recommendations: HIV-infected persons: Consider valganciclovir solution 100 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD):</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling: Use not recommended; ganciclovir (with appropriately specified renal dosage adjustment) should be used instead of valganciclovir.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate recommendations: HIV-1 infected persons: Consider valganciclovir solution 100 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234519'])">Ref</a></span>); valganciclovir is dialyzable and should be administered following dialysis.</p></div>
<div class="block dohp drugH1Div" id="F51193227"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F232909"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (12% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (6% to 22%), insomnia (6% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (16% to 41%), nausea (8% to 30%), vomiting (3% to 21%), abdominal pain (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≤31%), thrombocytopenia (≤22%), neutropenia (3% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Graft rejection (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (12% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinal detachment (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (S<sub>cr </sub>&gt;1.5 to 2.5 mg/dL: 12% to 50%; S<sub>cr </sub> &gt;2.5: 3% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (9% to 31%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≥5%), peripheral edema (≥5%), cardiac arrhythmia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Peripheral neuropathy (9%), paresthesia (≤8%), anxiety (≥5%), chills (≥5%), depression (≥5%), dizziness (≥5%), fatigue (≥5%), malaise (≥5%), pain (≥5%), agitation (&lt;5%), confusion (&lt;5%), hallucination (&lt;5%), psychosis (&lt;5%), seizure (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (≥5%), increased wound secretion (≥5%), night sweats (≥5%), pruritus (≥5%), cellulitis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (≥5%), hypophosphatemia (≥5%), weight loss (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (≥5%), constipation (≥5%), decreased appetite (≥5%), dyspepsia (≥5%), oral mucosa ulcer (≥5%), dysgeusia (&lt;5%), pancreatitis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (≥5%), urinary tract infection (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression (&lt;5%; including aplastic anemia), febrile neutropenia (&lt;5%), hemorrhage (&lt;5%; associated with thrombocytopenia), pancytopenia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency (≥5%), increased serum ALT (&lt;5%), increased serum AST (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Organ transplant rejection (6% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (≥5%; including oral candidiasis), influenza (≥5%), wound infection (≥5%), sepsis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≥5%), back pain (≥5%), muscle spasm (≥5%), myalgia (≥5%), weakness (≥5%), limb pain (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pain (≥5%), macular edema (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance (≥5%), renal impairment (≥5%), renal failure (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (≥5%), dyspnea (≥5%), pharyngitis (≥5%; including nasopharyngitis), upper respiratory tract infection (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Postoperative complication (≥5%), postoperative pain (&lt;5%), wound dehiscence (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Genitourinary: Reduced fertility</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Agranulocytosis, anaphylaxis, granulocytopenia</p></div>
<div class="block coi drugH1Div" id="F232922"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to acyclovir or valacyclovir</p></div>
<div class="block war drugH1Div" id="F232907"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute renal failure: Acute renal failure may occur; ensure adequate hydration and use with caution in patients receiving concomitant nephrotoxic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: <b>[US Boxed Warning]: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure, including aplastic anemia have been reported.</b> May occur at any time during treatment and worsen with continued use; cell counts usually begin to recover within 3 to 7 days of treatment discontinuation. Do not use in patients with an absolute neutrophil count &lt;500 cells/mm<sup>3</sup>, platelet count &lt;25,000/mm<sup>3</sup>, or hemoglobin &lt;8 g/dL; use with caution in patients with preexisting bone marrow suppression, cytopenias, or in those receiving myelosuppressive drugs/irradiation. Monitor CBC and platelet count at baseline and frequently during therapy, especially in infants and in patients with renal impairment, those with previous drug-induced leukopenia, and those with neutrophil counts &lt;1,000 cells/mm<sup>3</sup> at treatment initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinogenic/teratogenic: <b>[US Boxed Warning]: May cause temporary or permanent inhibition of spermatogenesis and suppression of fertility; has the potential to cause birth defects and cancers in humans.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with impaired renal function; dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older patients: Acute renal failure may occur in older patients with or without preexisting renal impairment; use with caution and adjust dose as needed based on renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Liver transplant recipients: Not indicated for use in liver transplant recipients (higher incidence of tissue-invasive cytomegalovirus [CMV] relative to oral ganciclovir was observed in trials).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir tablets may be used so long as the calculated dose is within 10% of the available tablet strength (450 mg). Use of valganciclovir for the treatment of congenital CMV disease has not been evaluated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878664"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The rates of certain adverse events and laboratory abnormalities, such as upper respiratory tract infection, pyrexia, nasopharyngitis, anemia, and neutropenia, were reported more frequently in pediatric patients than in adults in clinical trials. In a 6-month trial evaluating congenital cytomegalovirus treatment in neonates and infants, the reported incidence of grade 3 or 4 neutropenia was similar between valganciclovir and placebo (21% vs 27%) (Kimberlin 2015).</p></div>
<div class="block foc drugH1Div" id="F232917"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valcyte: 50 mg/mL (88 mL) [contains saccharin sodium, sodium benzoate; tutti-frutti flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (88 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valcyte: 450 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 450 mg</p></div>
<div class="block geq drugH1Div" id="F232903"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F232924"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Valcyte Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $14.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (valGANciclovir HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $8.48 - $11.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Valcyte Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">450 mg (per each): $106.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (valGANciclovir HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">450 mg (per each): $64.40 - $68.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868555"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valcyte: 50 mg/mL (100 mL) [contains propylene glycol, saccharin sodium, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valcyte: 450 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 450 mg</p></div>
<div class="block adm drugH1Div" id="F232919"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Valganciclovir should be administered with meals. Do not break or crush tablets.</p></div>
<div class="block admp drugH1Div" id="F52613994"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Due to the carcinogenic and mutagenic potential, avoid direct contact with broken or crushed tablets, powder for oral solution, and oral solution. Handle and dispose of valganciclovir according to guidelines issued for antineoplastic drugs.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with meals. The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir tablets may be used as long as the calculated dose is within 10% of the available tablet strength (450 mg). Do not break or crush tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Shake well prior to use. Use provided reusable oral syringe to measure and administer dose; do not use a household teaspoon, tablespoon, or other measuring device to measure dose (overdosage may occur).</p></div>
<div class="block hazard drugH1Div" id="F49132847"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F232918"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, prophylaxis in solid organ transplant recipients:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of cytomegalovirus (CMV) in high-risk adult patients (donor CMV seropositive/recipient CMV seronegative) undergoing kidney, heart, or kidney/pancreas transplantation.</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of CMV in high-risk pediatric patients undergoing kidney transplant (age 4 months to 16 years) or heart transplant (age 1 month to 16 years).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, treatment, retinitis:</b> Treatment of CMV retinitis in patients with AIDS.</p></div>
<div class="block off-label drugH1Div" id="F49367238"><span class="drugH1">Use: Off-Label: Adult</span><p>Cytomegalovirus, mild to moderate, treatment in solid organ transplant recipients; Cytomegalovirus, preemptive therapy in hematopoietic cell transplant recipients; Cytomegalovirus, treatment, esophagitis or colitis in patients with HIV</p></div>
<div class="block mst drugH1Div" id="F232970"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valcyte may be confused with Valium, Valtrex</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ValGANciclovir may be confused with acyclovir, valACYclovir, ganciclovir</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300203"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F232911"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Ganciclovir-Valganciclovir may increase the serum concentration of Didanosine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipenem: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased.  Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: May diminish the therapeutic effect of Ganciclovir-Valganciclovir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: May enhance the adverse/toxic effect of Ganciclovir-Valganciclovir. Specifically, the risk for leukopenia or neutropenia may be increased with this combination. Mycophenolate may increase the serum concentration of Ganciclovir-Valganciclovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Ganciclovir-Valganciclovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F232937"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Coadministration with a high-fat meal increased AUC by 30%. Management: Valganciclovir should be taken with meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F52597891"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who may become pregnant should undergo pregnancy testing prior to treatment with valganciclovir.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant should use effective contraception during treatment and for at least 30 days after therapy with valganciclovir. Patients with partners who could become pregnant should use condoms during treatment and for at least 90 days after valganciclovir therapy.</p>
<p style="text-indent:0em;margin-top:2em;">Based on animal data and limited human data, valganciclovir may cause temporary or permanent inhibition of spermatogenesis. Sperm density was decreased following 200 days of treatment with valganciclovir in patients following a renal transplant. Six months after treatment was discontinued, sperm density was comparable to transplant recipients who did not receive valganciclovir. Suppression of fertility may also occur in females.</p></div>
<div class="block pri drugH1Div" id="F232925"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Following maternal use of valganciclovir, ganciclovir can be detected in umbilical cord blood (Seidel 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Valganciclovir is converted to ganciclovir and shares its reproductive toxicity. Based on animal data, valganciclovir has the potential to cause birth defects in humans.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of valganciclovir for cytomegalovirus (CMV) infection during pregnancy are limited (Bergin 2014; DeNoble 2020; Seidel 2017).</p>
<p style="text-indent:0em;margin-top:2em;">CMV infection in immunocompromised patients is associated with significant maternal morbidity and mortality. Congenital CMV infection may also occur; hearing loss, intellectual disability, microcephaly, seizures, and other medical problems have been observed in infants with congenital CMV infection.</p>
<p style="text-indent:0em;margin-top:2em;">Until additional data are available, use of antivirals for the treatment of congenital CMV outside of a clinical trial is not currently recommended (SMFM 2016).</p>
<p style="text-indent:0em;margin-top:2em;">The indications for treating maternal CMV retinitis during pregnancy are the same as in non-pregnant HIV infected people. In general, intravitreous injections for local therapy are preferred for retinal disease to limit systemic exposure during the first trimester when possible. Valganciclovir is the preferred systemic therapy in pregnant patients (limited data). Close fetal monitoring is recommended. Use of valganciclovir is recommended to treat maternal infection, but not recommended for the treatment of asymptomatic maternal disease for the sole purpose of preventing infant infection (HHS [OI adult] 2021).</p></div>
<div class="block brc drugH1Div" id="F232926"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ganciclovir or valganciclovir are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer. In addition, the Health and Human Services perinatal HIV guidelines do not recommend breastfeeding for patients in the United States with HIV when safer infant feeding options are available (HHS [perinatal] 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Cytomegalovirus can also be transferred from mother to infant via breast milk; the risk of adverse outcomes if infection occurs is more likely in infants born &lt;32 weeks' gestation and &lt;1,500 g (Osterholm 2020).</p></div>
<div class="block dic drugH1Div" id="F232927"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Should be taken with meals.</p></div>
<div class="block mop drugH1Div" id="F232915"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, platelet count, serum creatinine at baseline and periodically during therapy; monitor CBC and platelet count more frequently during therapy in infants and in patients with renal impairment, those with previous drug-induced leukopenia, and those with neutrophil counts &lt;1,000 cells/mm<sup>3</sup> at treatment initiation; pregnancy test prior to initiation in females of reproductive potential.</p></div>
<div class="block pha drugH1Div" id="F232906"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Valganciclovir is rapidly converted to ganciclovir in the body. Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis.</p></div>
<div class="block phk drugH1Div" id="F232921"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed; high-fat meal increases AUC by 30%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Ganciclovir: 0.7 L/kg; widely to all tissue including CSF and ocular tissue.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Ganciclovir: 1% to 2%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Converted to ganciclovir by intestinal mucosal cells and hepatocytes.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: With food: 60%; similar in pediatric patients 4 months to 16 years; neonates: Initial data: 54% (Acosta 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients (heart, kidney, or liver transplant): Ganciclovir: Mean range:</p>
<p style="text-indent:-2em;margin-left:6em;">1 to &lt;4 months: 3.5 hours (heart transplant only).</p>
<p style="text-indent:-2em;margin-left:6em;">4 months to 2 years: Mean range: 2.8 to 4.5 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">2 to 12 years: Mean range: 2.8 to 4.8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">12 to 16 years: Mean range: 4.4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">Ganciclovir: 4.08 hours; prolonged with renal impairment; Severe renal impairment: Up to 68 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Heart, kidney, kidney-pancreas, or liver transplant recipients: Mean range: 6.18 to 6.77 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Ganciclovir: 1.7 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80% to 90%; primarily as ganciclovir).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F232928"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ganaxa | Valganciclovir sandoz | Valgard | Valixa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir Accord | Valganciclovir bluefish | Valganciclovir ratiopharm | Valganciclovir sandoz | Valganciclovir stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir amneal | Valganciclovir hetero | Valganciclovir juno | Valganciclovir sandoz</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alvanocyt | Valcyte</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de valganciclovir | Mafusa | Valcyte</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir mepha | Valganciclovir sandoz</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Citocit | Valgovir | Valixa | Volkired</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Gancix | Ganocip | Rivol x | Runavir | Trasgariv | Valganciclovir | Valgovir | Valixa | Valkir | Vangavir | Vilup | Viractin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir | Valganciclovir aurobindo | Valganciclovir sandoz | Valganciclovir teva | Virexan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Darilin | Valcyte | Valganaxiro | Valganciclovir | Valganciclovir bluefish | Valganciclovir glenmark | Valganciclovir heumann | Valganciclovir hexal | Valganciclovir Mylan | Valganciclovir stada</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Valixa</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Oxialcovir | Valganciclovir | Valixa | Valkir</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir Accord | Valganciclovir sandoz</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir Accord | Valganciclovir Aurovitas | Valganciclovir cipla | Valganciclovir normon | Valganciclovir sandoz | Valganciclovir tarbis | Valganciclovir teva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Valganciclovir</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir Accord | Valganciclovir orion</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rovalcyte | Valcyte | Valganciclovir Accord | Valganciclovir arrow | Valganciclovir biogaran | Valganciclovir cristers | Valganciclovir eg | Valganciclovir Mylan | Valganciclovir sandoz | Valganciclovir teva | Valganciclovir zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir | Valganciclovir cipla</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir | Valganciclovir sandoz</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valdamin | Valganciklovir onkogen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cymgal | Cytomega | Prothymo | V gavir | Valchek | Valgacel | Valgan | Valniche | Virolfi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Darilin | Valcyte | Valganciclovir Accord | Valganciclovir aurobindo | Valganciclovir Mylan | Valganciclovir sandoz | Valganciclovir teva italia</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Valixa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Vagacyte | Valchek | Valcyte</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">V gavir | Valcyte</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir arrow</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir Accord | Valganciclovir sandoz</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir Accord</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Rovalcyte</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Calex | Dempero | Dinegrol | Ecaltia | Trasgariv | Valcyte | Valganciclovir | Valnov | Wixeg | Zostev</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir | Valganciclovir Accord | Valganciclovir aurobindo | Valganciclovir Mylan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir Accord | Valganciclovir medical valley | Valganciclovir sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir | Valganciclovir Mylan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Valganciclovir | Valixa</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir | Valvir</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ceglar | Sperart | Valcyclox | Valcyte | Valganciclovir teva | Valhit</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Rovalcyte | Valganciclovir Accord | Valganciclovir Aurovitas | Valganciclovir bluepharma | Valganciclovir Mylan | Valganciclovir teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Detergan | V gabir | Valganciclovir dallas | Valganciclovir eticos | Valganciclovir promepar | Valganciclovir seven | Valixa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alvanocyt | Valcyte | Valganciclovir | Valganciclovir aurobindo | Valganciclovir sandoz | Valganciclovir zentiva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Civalgan | Valcyt | Valcyte | Valganciclovir | Valganciclovir teva | Valganolek</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valgan | Vercanza</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valganciclovir 2care4 | Valganciclovir abacus medicine | Valganciclovir Accord | Valganciclovir bluefish | Valganciclovir medartuum | Valganciclovir medical valley | Valganciclovir orion | Valganciclovir teva | Valganciklovir ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ganaxa | Valcyte | Valganciklovir stada</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valdamin | Valganciclovir Mylan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Avalcept | Citovir | Valcyte | Valganir</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Valcyte | Valgovir</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Valcyte</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Valixa</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cytameg | Valcyte | Valhet</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17392728">
<a name="17392728"></a>Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. <i>Clin Pharmacol Ther</i>. 2007;81(6):867-872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/17392728/pubmed" id="17392728" target="_blank">17392728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26207778">
<a name="26207778"></a>Atay D, Erbey F, Akcay A, Dag A, Ozturk G. Oral valganciclovir as preemptive therapy for cytomegalovirus reactivation in pediatric hematopoietic stem cell transplant patients. <i>J Pediatr Hematol Oncol</i>. 2015;37(7):543-547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/26207778/pubmed" id="26207778" target="_blank">26207778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24648317">
<a name="24648317"></a>Bergin S, Ferguson W, Corcoran S, et al. Symptomatic primary cytomegalovirus infection in a HIV-positive pregnant woman. <i>Int J STD AIDS</i>. 2014;25(14):1041-1043. doi:10.1177/0956462414528314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/24648317/pubmed" id="24648317" target="_blank">24648317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2019">
<a name="Bradley.2019"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19730409">
<a name="19730409"></a>Centers for Disease Control and Prevention (CDC). Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. <i>MMWR Recomm Rep.</i> 2009;58(RR-11):1-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/19730409/pubmed" id="19730409" target="_blank">19730409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15167619">
<a name="15167619"></a>Clark BS, Chang IF, Karpen SJ, et al. Valganciclovir for the Prophylaxis of Cytomegalovirus Disease in Pediatric Liver Transplant Recipients. <i>Transplantation.</i> 2004;77(9):1480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/15167619/pubmed" id="15167619" target="_blank">15167619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12189361">
<a name="12189361"></a>Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. <i>Clin Pharmacol Ther</i>. 2002;72(2):142-150. doi:10.1067/mcp.2002.126306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/12189361/pubmed" id="12189361" target="_blank">12189361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32198512">
<a name="32198512"></a>DeNoble AE, Saccoccio FM, Permar SR, Hughes BL. Prenatal treatment of congenital cytomegalovirus with valganciclovir: a case report.<i> Clin Infect Dis</i>. 2020;71(9):2506-2508. doi:10.1093/cid/ciaa305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/32198512/pubmed" id="32198512" target="_blank">32198512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17468661">
<a name="17468661"></a>Galli L, Novelli A, Chiappini E, et al. Valganciclovir for Congenital CMV Infection: A Pilot Study on Plasma Concentration in Newborns and Infants. <i>Pediatr Infect Dis J. </i>2007;26(5):451-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/17468661/pubmed" id="17468661" target="_blank">17468661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27639246">
<a name="27639246"></a>Heldenbrand S, Li C, Cross RP, et al. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. <i>Transpl Infect Dis</i>. 2016;18(6):904-912. doi: 10.1111/tid.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/27639246/pubmed" id="27639246" target="_blank">27639246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32379860">
<a name="32379860"></a>Jarrell AS, Crow JR, Strout SE, et al. Valganciclovir dosing for cytomegalovirus prophylaxis in solid organ transplant recipients on continuous veno-venous hemodialysis. <i>Clin Infect Dis</i>. Published online May 7, 2020. doi:10.1093/cid/ciaa537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/32379860/pubmed" id="32379860" target="_blank">32379860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18279073">
<a name="18279073"></a>Kimberlin DW, Acosta EP, Sánchez PJ, et al. Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease. <i>J Infect Dis.</i> 2008;197(6):836-845.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/18279073/pubmed" id="18279073" target="_blank">18279073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25738669">
<a name="25738669"></a>Kimberlin DW, Jester PM, Sánchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. <i>N Engl J Med</i>. 2015;372(10):933-943.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/25738669/pubmed" id="25738669" target="_blank">25738669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29596116">
<a name="29596116"></a>Kotton CN, Kumar D, Caliendo AM, et al; The Transplantation Society International CMV Consensus Group. The Third International Consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. <i>Transplantation</i>. 2018;102(6):900-931. doi: 10.1097/TP.0000000000002191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/29596116/pubmed" id="29596116" target="_blank">29596116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20477976">
<a name="20477976"></a>Lapidus-Krol E, Shapiro R, Amir J, et al. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. <i>Pediatr Transplant</i>. 2010;14(6):753-760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/20477976/pubmed" id="20477976" target="_blank">20477976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22198827">
<a name="22198827"></a>Launay E, Théôret Y, Litalien C, et al. Pharmacokinetic profile of valganciclovir in pediatric transplant recipients. <i>Pediatr Infect Dis J</i>. 2012;31(4):405-407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/22198827/pubmed" id="22198827" target="_blank">22198827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23640298">
<a name="23640298"></a>Le Page AK, Jager MM, Kotton CN, Simoons-Smit A, Rawlinson WD. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. <i>Transplantation</i>. 2013;95(12):1455-1460. doi: 10.1097/TP.0b013e31828ee12e.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/23640298/pubmed" id="23640298" target="_blank">23640298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11929799">
<a name="11929799"></a>Ljungman P, de La Camara R, Milpied N, et al. Randomized Study of Valacyclovir as Prophylaxis Against Cytomegalovirus Reactivation in Recipients of Allogeneic Bone Marrow Transplants. <i>Blood.</i> 2002;99(8):3050-3056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/11929799/pubmed" id="11929799" target="_blank">11929799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19763643">
<a name="19763643"></a>Lombardi G, Garofoli F, Villani P, et al. Oral Valganciclovir Treatment in Newborns With Symptomatic Congenital Cytomegalovirus Infection. <i>Eur J Clin Microbiol Infect Dis.</i> 2009;28(12):1465-1470.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/19763643/pubmed" id="19763643" target="_blank">19763643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234519">
<a name="25234519"></a>Lucas GM, Ross MJ, Stock PG, et al. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9):e96-e138. doi:10.1093/cid/ciu617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/25234519/pubmed" id="25234519" target="_blank">25234519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32662174">
<a name="32662174"></a>Osterholm EA, Schleiss MR. Impact of breast milk-acquired cytomegalovirus infection in premature infants: pathogenesis, prevention, and clinical consequences? <i>Rev Med Virol.</i> 2020;30(6):1-11. doi:10.1002/rmv.2117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/32662174/pubmed" id="32662174" target="_blank">32662174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10991864">
<a name="10991864"></a>Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients. <i>Antimicrob Agents Chemother.</i> 2000;44(10):2811-2815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/10991864/pubmed" id="10991864" target="_blank">10991864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16368917">
<a name="16368917"></a>Peyriere H, Jeziorsky E, Jalabert A, et al. Neurotoxicity Related to Valganciclovir in a Child With Impaired Renal Function: Usefulness of Therapeutic Drug Monitoring. <i>Ann Pharmacother</i>. 2006;40(1):143-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/16368917/pubmed" id="16368917" target="_blank">16368917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24010993">
<a name="24010993"></a>Posadas Salas MA, Taber DJ, Chua E, Pilch N, Chavin K, Thomas B. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. <i>Transpl Infect Dis</i>. 2013;15(6):551-558. doi:10.1111/tid.12133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/24010993/pubmed" id="24010993" target="_blank">24010993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30817026">
<a name="30817026"></a>Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13512. doi:10.1111/ctr.13512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/30817026/pubmed" id="30817026" target="_blank">30817026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32892447">
<a name="32892447"></a>Schaenman J, Phonphok K, Spanuchart I, et al. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients. <i>Transpl Infect Dis</i>. 2021;23(1):e13457. doi:10.1111/tid.13457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/32892447/pubmed" id="32892447" target="_blank">32892447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28733760">
<a name="28733760"></a>Seidel V, Feiterna-Sperling C, Siedentopf JP, et al. Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature. <i>Med Microbiol Immunol.</i> 2017;206(5):347-354. doi:10.1007/s00430-017-0512-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/28733760/pubmed" id="28733760" target="_blank">28733760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076649">
<a name="30076649"></a>Shaikh S, Jasiak-Panek N, Park JM. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients. <i>Clin Transplant</i>. 2018;32(9):e13369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/30076649/pubmed" id="30076649" target="_blank">30076649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26902990">
<a name="26902990"></a>Society for Maternal-Fetal Medicine (SMFM), Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. <i>Am J Obstet Gynecol.</i> 2016;214(6):B5-B11. doi:10.1016/j.ajog.2016.02.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/26902990/pubmed" id="26902990" target="_blank">26902990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29546589">
<a name="29546589"></a>Tängdén T, Cojutti PG, Roberts JA, Pea F. Valganciclovir pharmacokinetics in patients receiving oral prophylaxis following kidney transplantation and model-based predictions of optimal dosing regimens. <i>Clin Pharmacokinet</i>. 2018;57(11):1399-1405. doi:10.1007/s40262-018-0638-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/29546589/pubmed" id="29546589" target="_blank">29546589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23733466">
<a name="23733466"></a>Trevillyan J, Angus P, Shelton E, et al. Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir. <i>Antimicrob Agents Chemother</i>. 2013;57(8):4058-4060. doi:10.1128/AAC.00375-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/23733466/pubmed" id="23733466" target="_blank">23733466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed January 5, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/Adult_OI003657.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/Adult_OI003657.pdf</a>. Updated July 1, 2021. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/oi_guidelines_pediatrics.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/oi_guidelines_pediatrics.pdf</a>.Updated December 9, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valcyte.1">
<a name="Valcyte.1"></a>Valcyte (valganciclovir) [prescribing information]. South San Francisco, CA: Genentech Inc; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valcyte.2">
<a name="Valcyte.2"></a>Valcyte (valganciclovir) [prescribing information]. Montgomery, AL: H2-Pharma LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valcyte.3">
<a name="Valcyte.3"></a>Valcyte (valganciclovir) [product monograph]. Mississauga, Ontario, Canada: Xediton Pharmaceuticals Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19260840">
<a name="19260840"></a>Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. <i>Am J Transplant</i>. 2009;9(3):636-643.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/19260840/pubmed" id="19260840" target="_blank">19260840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28060118">
<a name="28060118"></a>Wattles BA, Kim AJ, Cheerva AC, Lucas KG, Elder JJ. Cytomegalovirus treatment in pediatric hematopoietic stem cell transplant patients. <i>J Pediatr Hematol Oncol</i>. 2017;39(4):241-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valganciclovir-drug-information/abstract-text/28060118/pubmed" id="28060118" target="_blank">28060118</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10058 Version 370.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
